Innovative approaches for lung cancer screening and interception - PubMed
2 months ago
- #biomarkers
- #screening
- #lung cancer
- Lung cancer is the leading cause of cancer-related deaths globally, often diagnosed at late stages.
- Low-dose computed tomography (LDCT) screening reduces mortality but has low uptake and misses nearly half of lung cancers in ineligible individuals.
- LDCT screening has limitations like high false-positive rates and substantial costs.
- Novel biomarkers, such as radiomic features and liquid biopsy assays, are being developed to improve risk prediction.
- Therapeutic interventions are needed to intercept high-risk precancerous nodules detected by LDCT or diagnostic CT scans.
- Current efforts focus on addressing disparities, improving infrastructure, and developing biomarkers for better screening and interception strategies.